Signals, Powered By EquityPandit
Strides Shasun has received pre-qualification for its rectal artesunate product for the pre-referral management of severe malaria, from the World Health Organization (WHO).
In a filing to BSE the company stated that, the pre-qualification for the 100mg rectal artesunate suppositories (RAS) has been achieved with support from Medicines for Malaria Venture (MMV) and funding from Unitaid. This pre-qualification allows countries to purchase life-saving RAS with donor funding, thereby ensuring increased access to this potentially life-saving intervention.
Further, Arun Kumar, CEO and MD of Strides stated, “We are honored to have collaborated with MMV and Unitaid on this project and to have now received WHO approval for our novel-delivery soft-gel artesunate suppositories for use in children suffering from severe malaria.”
